HeraMED Limited (ASX:HMD) is an innovative medical data and technology company leading the digital transformation of the prenatal and postpartum experience through its revolutionary remote monitoring and hybrid maternity care platform. HeraMED’s state of the art in-home fetal and maternal heart rate monitor, HeraBEAT, is medically accurate, scientifically optimized and smartphone-based. It provides seamless data sharing of maternal and fetal vital signs with medical professionals via the company’s platform HeraCARE. HeraCARE is a complete remote maternity care platform designed to power personalized, safe, proactive care for both patients and providers. The hybrid care model made possible by HeraCARE makes remote monitoring of vital signs including blood pressure, weight, FHR, mood, and more possible. Patients and providers experience action-driven alerts when any measurement falls outside 'normal' range. Plus, patients have 24/7 access to comprehensive educational content, lifestyle guidance, pregnancy management tools, and support. HeraMED’s technology has been recognised by major medical institutions, with collaborations underway with the Mayo Clinic and the Sheba Medical Center, two of the world’s top 10 hospitals. Through its partnerships and investment in R&D, HeraMED continues to optimise and develop the next generation of its home-oriented monitoring technology. To learn more, please visit: www.hera-med.com/